Abstract

Introduction

Neoadjuvant chemoradiotherapy (NA CRT) has shown benefit in overall survival (OS) in patients with locally advanced esophageal carcinoma. However, toxicity and postoperative morbidity are not negligible.

Methods

We retrospectively reviewed patients with locally advanced esophageal carcinoma treated at Catalan Institute of Oncology and integrated centers who underwent NA CRT from 2009 to 2013. G3/4 toxicity and postoperative complications were recorded. OS and disease free survival (DFS) curves and medians were performed by using Kaplan Meier method as well as identification of prognostic factors using multivariate Cox regression.

Conclusion

NA CRT is a safe strategy for locally advanced esophageal carcinoma in selected pts, who have been treated with multidisciplinary approach. It improves R0 rate and tumor downstaging with similar results than previous reports. ADC and SCC represent two distinct diseases with different epidemiology and prognosis. However, no significant differences were achieved in our cohort probably due to small number of pts.